Ganoderic Acids from Ganoderma lucidum: Inhibitory Activity of Osteoclastic Differentiation and Structural Criteria

Abstract

Increased osteoclastic bone resorption plays a central role in the pathogenesis of many bone diseases. Ganoderma lucidum is known for medicinal effects such as anti-inflammatory and anti-bone resorption activities. In this study, we investigated the inhibitory effects of ganoderic acids isolated from G. lucidum on osteoclastic differentiation using RAW264 cells in vitro. A carbonyl in C7 is essential to elicit the inhibition of osteoclast differentiation.

Key words

Ganoderma lucidum - Ganodermataceae - triterpenoids - ganoderic acids - osteoclastic differentiation

References

• 1 Manolagas S C. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis.  Endocr Rev. 2000;  21 115-137
• 2 Suda T, Takahashi N, Martin T J. Modulation of osteoclast differentiation.  Endocr Rev. 1992;  13 66-80
• 3 Asagiri M, Takayanagi H. The molecular understanding of osteoclast differentiation.  Bone. 2007;  40 251-264
• 4 Tang W, Hemm I, Bertram B. Recent development of antitumor agents from Chinese herbal medicines. Part II. High molecular compounds.  Planta Med. 2003;  3 193-201
• 5 Hikino H, Mizuno T. Hypoglycemic actions of some heteroglycans of Ganoderma lucidum fruit bodies.  Planta Med. 1989;  4 385
• 6 Miyamoto I, Liu J, Shimizu K, Sato M, Kukita A, Kukita T, Kondo R. Regulation of osteoclastogenesis by ganoderic acid DM isolated from Ganoderma lucidum.  Eur J Pharmacol. 2009;  602 1-7
• 7 Yue Q X, Xie F B, Guan S H, Ma C, Yang M, Jiang B H, Liu X, Guo D A. Interaction of Ganoderma triterpenes with doxorubicin and proteomic characterization of the possible molecular targets of Ganoderma triterpenes.  Cancer Sci. 2008;  99 1461-1470
• 8 Komoda Y, Nakamura H, Ishihara S, Uchida M, Kohda H, Yamasaki K. Structures of new terpenoid constitutents of Ganoderma lucidum (FR.) KARST. (Polyporaceas).  Chem Pharm Bull. 1985;  33 4829-4835
• 9 Arisawa M, Fujita A, Hayasi T, Shimizu M, Morita N, Kikuchi T, Kadota S, Tezuka Y. Revision of ¹H- and ¹³C-NMR assignments of lanostanoids from Ganoderma lucidum by 2D-NMR studies.  J Nat Prod. 1988;  51 54-59
• 10 Liu J, Kurashiki K, Shimizu K, Kondo R. Structure activity relationship for inhibition of 5α: reductase by triterpenoids isolated from Ganoderma lucidum.  Bioorg Med Chem. 2006;  14 8654-8660
• 11 Watanabe T, Kukita T, Kukita A, Wada N, Toh K, Nagata K, Nomiyama H, Iijima T. Direct stimulation of osteoclastogenesis by MIP-1α: evidence obtained from studies using RAW264 cell clone highly responsive to RANKL.  J Endocrinol. 2004;  180 193-201
• 12 Liu J, Shiono J, Shimizu K, Yu H S, Zhang C Z, Jin F X, Kondo R. 20(R)-Ginsenoside Rh2, not 20(S), is a selective osteoclastogenesis inhibitor without any cytotoxicity.  Bioorg Med Chem Lett. 2009;  19 3320-3323